Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.95M | 2.71M | 3.62M | 3.10M | 2.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.43M | 4.91M | 6.92M | 5.46M | 2.19M |
| Operating Income | -7.43M | -4.91M | -6.92M | -5.46M | -2.19M |
| Income Before Tax | -7.76M | -5.12M | -7.04M | -5.54M | -1.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.76M | -5.12M | -7.04M | -5.54M | -1.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.76M | -5.12M | -7.04M | -5.54M | -1.59M |
| EBIT | -7.43M | -4.91M | -6.92M | -5.46M | -2.19M |
| EBITDA | -7.42M | -4.90M | -6.92M | -5.46M | -2.18M |
| EPS Basic | -3.04 | -2.01 | -2.76 | -2.61 | -1.34 |
| Normalized Basic EPS | -1.90 | -1.25 | -1.72 | -1.63 | -0.84 |
| EPS Diluted | -3.04 | -2.01 | -2.76 | -2.61 | -1.34 |
| Normalized Diluted EPS | -1.90 | -1.25 | -1.72 | -1.63 | -0.84 |
| Average Basic Shares Outstanding | 2.55M | 2.55M | 2.55M | 2.13M | 1.19M |
| Average Diluted Shares Outstanding | 2.55M | 2.55M | 2.55M | 2.13M | 1.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |